Syncona enjoys value uplift after Quell completes £117mln funding round
The company will own a 37% stake in the immune system specialist
Company
LON:SYNC
Syncona Limited is a leading healthcare company focused on founding, building and funding global leaders in life science. Syncona is aligned with two of the premium charitable funders in UK science, The Wellcome Trust, original founder of Syncona, and Cancer Research UK, both of which are significant shareholders.
12 stories
The company will own a 37% stake in the immune system specialist
The news is also a blow to FTSE 250-listed Syncona, which recently upped its stake to 54%
FTSE 250-listed Syncona will retain a 27% stake in Achilles, in which it invested five years ago
Achilles has also been greenlighted to advance its ongoing clinical trials.
The life sciences group's portfolio value rose 35.1% to £677mln, while its net asset value jumped 13.5% to 210.7p per share
The gene therapy group will list on the Nasdaq Global Select Market on Friday with its shares priced at US$18 each
The company’s life sciences portfolio suffered a 25% decline over its previous financial year as uplifts from company sales were offset by an 81% decline in the Autolus stock
Syncona has once again backed Gyroscope and Achilles, which are developing treatments for eye conditions and cancer, respectively
Archive
Investments and investor services
The FTSE 100 has clawed back all of this morning's losses and some, while the ECB has unveiled plans to end its quantitative easing programme in December
Archive
Aside from the ECB meeting, the day ahead also includes an annual general meeting for Wm Morrison Supermarkets, and updates from PZ Cussons and Majestic Wine
A reshuffle of the FTSE 100 and FTSE 250 indices will be announced tomorrow, determined by today's closing prices